Table 2

Response rates*

Non-switchers (n=437)Switchers (n=77)
1st TNFi1st TNFi2nd TNFi
3 Months3 MonthsLast observation3 Monthsp Valuep Value§
(n=362)(n=63)(n=68)(n=62)
BASDAI 50, n (%)105 (50.0)6 (25.0)2 (22.2)13 (28.3)0.0071.00
n=202n=23n=25n=45
ASAS20, n (%)106 (52.5)11 (47.8)7 (28.0)18 (40.0)0.131.00
ASAS40, n (%)76 (37.6)7 (30.4)4 (16.7)14 (31.1)0.411.00
n=168n=19n=22n=35
ΔASDAS ≥1.1 (Clinically Important Improvement), n (%)94 (56.0)11 (57.9)8 (36.4)17 (48.6)0.421.00
ΔASDAS ≥2.0 (Major Improvement), n (%)51 (30.4)2 (10.5)2 (9.1)11 (31.4)0.900.38
  • * BASDAI 50, ASAS and ASDAS responses were not available for all patients (see details in text).

  • 3 months, n=17; 6 months, n=24; 1 year, n=9; 2 years, n=10; 3 years, n=3; 4 years, n=2.

  • Non-switchers first TNFi vs switchers second TNFi (χ2test).

  • § Switchers first TNFi (3 months) vs switchers second TNFi (McNemar test).

  • ASAS, Assessments of Spondyloarthritis International Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; TNFi, tumour necrosis factor inhibitor.